Revenue Increased 12% Year-Over-Year Record Non-Prostate Brachytherapy Revenue Increased 28% Year-Over-Year RICHLAND, WASHINGTON – November 10, 2022 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering...
Fourth Consecutive Quarter of Year-Over-Year Revenue Increases RICHLAND, Wash., Feb. 08, 2018 (GLOBE NEWSWIRE) -- IsoRay, Inc. (NYSE American:ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment...
RICHLAND, Jan. 31, 2018 (GLOBE NEWSWIRE) -- - IsoRay, Inc. (the “Company”) (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and...
Revenue Increase Driven by Increasing Traction of New Sales Strategies in Prostate Brachytherapy RICHLAND, Wash, Jan. 24, 2018 (GLOBE NEWSWIRE) -- -- IsoRay, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy and medical...
Revenue of $1.21 Million, 12% First Quarter-Over-First Quarter Increase, Gross Margin of 22% RICHLAND, Wash., Nov. 14, 2017 (GLOBE NEWSWIRE) -- IsoRay, Inc. (NYSE MKT:ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope...
Gross Margin Expands to 36% on Continued Process Improvements and Expense Reduction RICHLAND, Wash., Sept. 28, 2017 /PRNewswire/ -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for...
Gross Margin Expands Significantly to 31% on Ongoing Process Improvements and Expense Reduction RICHLAND, Wash., Aug. 4, 2017 /PRNewswire/ -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope...
Management Continues to Expect Stronger Second Half of Fiscal 2017 RICHLAND, Wash., Feb. 8, 2017 /PRNewswire/ -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of...
Management Continues to Expect Stronger Second Half of Fiscal 2017 RICHLAND, Wash., Nov. 8, 2016 /PRNewswire/ -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of...
Management Presenting at Rodman & Renshaw 18th Annual Global Investment Conference on Tuesday, September 13, 2016 at 10:00 am ET RICHLAND, Wash., Sept. 8, 2016 /PRNewswire/ -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed...
RICHLAND, Wash., May 10, 2016 /PRNewswire/ -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers,...
12% Revenue Growth in The 2nd Quarter 2016 Over 2nd Quarter 2015 RICHLAND, Wash., Feb. 10, 2016 /PRNewswire/ -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of...